Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by irreversibly inhibiting the H+/K+-ATPase enzyme system in the gastric parietal cell. It is available in oral delayed-release tablets and intravenous (IV) formulations.
## Primary Indications
* Erosive esophagitis associated with GERD.
* Maintenance of healing of erosive esophagitis.
* Pathological hypersecretory conditions (including Zollinger-Ellison syndrome).
* Prophylaxis of stress-related mucosal bleeding (off-label ICU use).
## Adult Dosing
* **GERD/Erosive Esophagitis:** 40 mg PO or IV once daily for up to 8 weeks.
* **Maintenance:** 40 mg PO once daily.
* **Hypersecretory Conditions:** Starting dose 40 mg PO twice daily. Doses up to 240 mg/day have been utilized; titration should be based on clinical response.
* **Stress Ulcer Prophylaxis:** 40 mg IV once daily (note: routine prophylaxis in non-ICU patients is generally discouraged).
## Pediatric Dosing
* **GERD (5 years and older):**
* 15 kg to <40 kg: 20 mg PO once daily.
* ≥ 40 kg: 40 mg PO once daily.
* **IV Dosing:** Safety and efficacy in pediatric patients for IV use have not been clearly established by the FDA; clinical protocols vary significantly.
## Dose Adjustments
* **Hepatic Impairment:** No specific adjustment required for mild to moderate impairment. Severe impairment may require dose reduction; monitor for liver enzyme elevations.
* **Renal Impairment:** No adjustment required.
* **Geriatric:** No adjustment required based on age alone.
## Contraindications
* Known hypersensitivity to pantoprazole or any substituted benzimidazole (e.g., omeprazole, lansoprazole).
* Concomitant use with rilpivirine-containing products.
## Adverse Effects
* **Common:** Headache, diarrhea, abdominal pain, flatulence.
* **Serious:** *Clostridioides difficile*-associated diarrhea, hypomagnesemia, vitamin B12 deficiency (with long-term use), acute interstitial nephritis, and increased risk of bone fractures (osteoporosis-related).
## Key Drug Interactions
* **pH-Dependent Drugs:** May decrease absorption of ketoconazole, atazanavir, and iron salts.
* **Clopidogrel:** Potential reduction in the antiplatelet effect of clopidogrel (clinical significance remains debated).
* **Methotrexate:** High-dose methotrexate serum levels may be elevated in patients using PPIs.
## Monitoring
* **Long-term use:** Monitor serum magnesium levels periodically.
* **Clinical:** Assess for signs of nutritional deficiencies (B12) if usage exceeds 12 months.
* **Symptoms:** Monitor for resolution of reflux symptoms or alarm symptoms (e.g., dysphagia, weight loss, hematemesis).
## Clinical Pearls
* **Administration:** Oral tablets should be swallowed whole; do not crush or chew. IV pantoprazole should be administered as a slow, 15-minute infusion or bolus injection over 2 minutes (depending on facility policy).
* **Deprescribing:** Attempt to taper or discontinue PPIs if the patient no longer meets the criteria for prophylactic or chronic acid suppression to avoid long-term adverse effects.
* **Efficacy:** Acid suppression is maximized after a few days of consistent daily dosing; it is not intended for "as-needed" rescue therapy for acute heartburn.
***
**Educational Disclaimer:** This information is for educational purposes only. Clinical practices vary by institution. Always verify dosages, contraindications, and drug interactions against current, authoritative resources (e.g., institutional formulary, Lexicomp, or the FDA-approved package insert) before prescribing or administering medication.
